Download
10.1007_s00228-017-2335-y.pdf 1,05MB
WeightNameValue
1000 Titel
  • Analysis of integrated clinical trial protocols in early phases of medicinal product development
1000 Autor/in
  1. Fruhner, Kevin |
  2. Hartmann, Gunther |
  3. Sudhop, Thomas |
1000 Erscheinungsjahr 2017
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2017-09-18
1000 Erschienen in
1000 Quellenangabe
  • 73:1565–1577
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2017
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00228-017-2335-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684304/ |
1000 Ergänzendes Material
  • https://link.springer.com/article/10.1007%2Fs00228-017-2335-y#SupplementaryMaterial |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and more popular. The aims of the present study were to investigate the usage and the impact of integrated protocols on regulatory activities and to find the motivation for their increasing use. METHODS: Two thousand nine hundred sixty-nine phase I and I/II CTAs submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) during the time period from August 1, 2004, until August 31, 2014, were analysed with regard to protocol and sponsor status, duration until initial authorisation and the number of substantial amendments and their respective approval times. Additionally, applicants who submitted integrated protocols to BfArM were interviewed with respect to their opinion on integrated protocols in an online survey. RESULTS: The percentage of integrated protocols has constantly increased by approximately 10% within the last 10 years from 17.9% in 2004 to 28.2% in 2014. It could be shown that authorisation procedures with single integrated protocols take significantly longer until initial authorisation (58 vs. 53 days) requires more substantial amendments (1.9 vs. 1.2 amendments per CTA) and the approval of the entirety of amendments takes longer to process as compared to standard protocols (22 vs. 14 days). Nevertheless, applicants prefer the use of integrated protocols due to higher time and cost economy for the entire phase I development process. CONCLUSION: Although clinical trials (CTs) following integrated protocols are partly more time-consuming and costly, still, time and/or money may be saved during drug development due to the fact that overall, fewer CTs are needed than with standard protocols. Hence, the main reason for the increasing use of integrated protocols is improved time and cost efficiencies when conducting CTs.
1000 Sacherschließung
lokal Integrated protocol
lokal Non-integrated (standard) protocol
lokal Early-phase clinical trials
lokal Federal Institute for Drugs and Medical Devices (BfArM)
lokal Substantial amendment
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/RnJ1aG5lciwgS2V2aW4g|https://frl.publisso.de/adhoc/creator/SGFydG1hbm4sIEd1bnRoZXIg|http://orcid.org/0000-0002-6780-587X
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6407550.rdf
1000 Erstellt am 2018-04-11T13:58:48.902+0200
1000 Erstellt von 281
1000 beschreibt frl:6407550
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet Tue Oct 25 15:36:11 CEST 2022
1000 Objekt bearb. Tue Oct 25 15:36:11 CEST 2022
1000 Vgl. frl:6407550
1000 Oai Id
  1. oai:frl.publisso.de:frl:6407550 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source